Bio-Rad Q2 revenue up 2.1%, beats estimates

Bio-Rad Laboratories

31/07/2025 21:24

Overview

Bio-Rad Q2 2025 revenue rises 2.1% yr/yr, beating analyst expectations

Adjusted EPS for Q2 2025 beats consensus, reflecting effective expense management

Co completes acquisition of Stilla Technologies, enhancing Droplet Digital PCR offerings

Outlook

Bio-Rad expects full-year revenue growth of 0 to 1.0 percent

Company revises full-year operating margin to 12.0 to 13.0 percent

Result Drivers

PROCESS CHROMATOGRAPHY - Increased sales of process chromatography products drove revenue growth

DIABETES TESTING REIMBURSEMENTS - Lower reimbursements for diabetes testing in China impacted Clinical Diagnostics segment sales

ACQUISITION IMPACT - Acquisition of Stilla Technologies expanded Droplet Digital PCR offerings, contributing to revenue growth

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Sales
Beat
$651.60 mln
$615.20 mln (6 Analysts)
Q2 Adjusted EPS
Beat
$2.61
$1.73 (6 Analysts)
Q2 EPS
$11.67
Q2 Net Income
$317.80 mln
Q2 Gross Margin
53.0%


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for Bio Rad Laboratories Inc is $317.50, about 21.2% above its July 30 closing price of $250.08

The stock recently traded at 28 times the next 12-month earnings vs. a P/E of 24 three months ago

Press Release: ID:nBw9dwVm2a

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)